AT7519M + bortezomib

AT7519M + bortezomib is an investigational combination therapy for the treatment of multiple myeloma, particularly in patients with relapsed or refractory disease. **AT7519M** is a potent, ATP-competitive multi-cyclin dependent kinase (CDK) inhibitor with strong activity against CDK1, CDK2, CDK4, CDK6, and especially CDK9, leading to inhibition of transcription via RNA polymerase II, cell cycle arrest, and apoptosis in tumor cells. **Bortezomib** is a reversible inhibitor of the 26S proteasome, leading to disruption of protein degradation pathways and induction of apoptosis in cancer cells. The combination has shown enhanced clinical activity, with higher response rates compared to AT7519M alone, in early-phase clinical trials for patients with advanced multiple myeloma. The maximum tolerated doses were 21 mg/m² for AT7519M and 1.3 mg/m² for bortezomib. The combination was generally well tolerated and demonstrated a 33% partial remission or better in heavily pretreated patients[1][2][5].

Other names

AT-7519M + bortezomib